Assessing the effectiveness of a specialist cancer nurse-led telehealth model of care on pain and symptom management among Australians affected by pancreatic cancer: The PANConnect randomised controlled trial

Peter MacCallum Cancer Centre0 sites146 target enrollmentAugust 27, 2024

Overview

No summary available.

Registry

who.int

Start Date

August 27, 2024

End Date

TBD

Last Updated

last year

Study Type

Interventional

Sex

All

Sponsor

Peter MacCallum Cancer Centre

•Patients with pancreatic cancer, family members and support people (carers) of patients with pancreatic cancer, healthcare professionals providing care to patients with pancreatic cancer at trial sites and the study specialist nurses delivering the intervention will be invited to participate.
•Patients with pancreatic cancer are eligible to participate if they:
•1\.Are aged 18 years or older;
•2\.Have a confirmed diagnosis of pancreatic adenocarcinoma at any stage, independent of resectability;
•3\.Have a life expectancy of at least three months, as indicated by their treating consultant;
•4\.Have a documented cancer treatment plan in place, known to the patient; and
•5\.Are receiving their initial care at a trial site.
•Carers are eligible to participate if they:
•1\.Are aged 18 years or older;
•2\.Able to speak and read English.

•Patients with pancreatic cancer will not be eligible if they do not have capacity to provide informed consent (e.g., suffering from dementia or delirium). In addition, participants who do not have access to a telephone (mobile or landline) will not be eligible to participate.